3-chloro-2-ethylbenzoic acid | 67648-15-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-chloro-2-ethylbenzoic acid
• 英文别名: 3-Chlor-2-ethylbenzoesaeure
• CAS: 67648-15-1
• 化学式: C₉H₉ClO₂
• 分子量: 184.622
• InChiKey: WAJWCFNSNAGTIL-UHFFFAOYSA-N

物化性质

• 熔点：
  126-128 °C
• 沸点：
  286.7±20.0 °C(Predicted)
• 密度：
  1.258±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-chloro-2-ethylbenzoic acid 生成 7-chloro-8-ethyl-1,2,3,4-tetrahydroisoquinoline
  参考文献：
  名称：

  Pharmaceutical compositions and methods of inhibiting phenylethanolamine

  摘要：

  制药组合物和使用7和/或8取代的1,2,3,4-四氢异喹啉化合物抑制苯乙醇胺N-甲基转移酶的方法。

  公开号：

  US03988339A1
• 作为产物：
  描述：

  碘乙烷 、 3-氯苯甲酸 在 四甲基乙二胺 、 仲丁基锂 作用下， 以 四氢呋喃 为溶剂， 以41%的产率得到3-chloro-2-ethylbenzoic acid
  参考文献：
  名称：

  Bennetau, Bernard; Mortier, Jacques; Moyroud, Joel, Journal of the Chemical Society. Perkin transactions I, 1995, # 10, p. 1265 - 1272

  摘要：

  DOI：

文献信息

• NOVEL BICYCLIC NITROGEN CONTAINING HETEROARYL TGR5 RECEPTOR MODULATORS
  申请人：Robl Jeffrey A.

  公开号：US20140080788A1

  公开（公告）日：2014-03-20

  Novel compounds of Formula I:or an enantiomer, diastereomer, tautomer, prodrug or salt thereof, wherein m, Q, T, U, V, ring A, X, Y, R 3 , R 4 , R 4a , R 5a , R 5b , R 5c , R 5d , R 5e , R 6a , R 6b , and R 6c are defined herein, are provided which are TGR5 G protein-coupled receptor modulators. TGR5 G protein-coupled receptor modulators are useful in treating, preventing, or slowing the progression of diseases requiring TGR5 G protein-coupled receptor modulator therapy. Thus, the disclosure also concerns compositions comprising these novel compounds and methods of treating diseases or conditions related to the activity of the TGR5 G protein-coupled receptor by using any of these novel compounds or a composition comprising any of such novel compounds.

  本发明提供了一种公式I的新化合物：或其对映异构体、顺反异构体、互变异构体、前药或其盐，其中m、Q、T、U、V、环A、X、Y、R3、R4、R4a、R5a、R5b、R5c、R5d、R5e、R6a、R6b和R6c的定义如本文所述，这些化合物是TGR5 G蛋白偶联受体调节剂。 TGR5 G蛋白偶联受体调节剂在治疗、预防或减缓需要TGR5 G蛋白偶联受体调节剂治疗的疾病方面具有用途。因此，本公开还涉及包含这些新化合物的组合物以及使用任何这些新化合物或包含任何这些新化合物的组合物来治疗与TGR5 G蛋白偶联受体活性相关的疾病或病症的方法。
• Heteroaryl sulfonamides and CCR2
  申请人：ChemoCentryx, Inc.

  公开号：EP2474532A1

  公开（公告）日：2012-07-11

  A compound of the formula (I), or a salt thereof: where Ar is selected from the group consisting of substituted or unsubstituted C6-10 aryl and substituted or unsubstituted 5- to 10-membered heteroaryl; R1 is selected from the group consisting of hydrogen, unsubstituted C1 alkyl, substituted or unsubstituted C3-8 alkyl, substituted or unsubstituted C2-6 alkenyl, substituted or unsubstituted C2-6 alkynyl, and substituted or unsubstituted 3- to 10-membered heterocyclyl; Y1 is selected from the group consisting of -CR2a-, -N-, and -N+(O)--; Y2 is selected from the group consisting of -CR2b-, -N-, and -N+(O)--; Y3 is selected from the group consisting of -CR2c-, -N-, and -N+(O)--; R2a, R2b, and R2c are each independently selected from the group consisting of hydrogen, halogen, -CN, -C(O)R3, -CO2R3, -C(O)NR3R4, -OR3, - OC(O)R3, -OC(O)NR3R4, -SR3, -S(O)R3, -S(O)2R3, -S(O)2NR3R4, -NO2, -NR3R4, -NR3C(O)R4, -NR3C(O)OR4, -NR3S(O)2R4, -NR3C(O)NR4R5, substituted or unsubstituted C1-8 alkyl, substituted or unsubstituted C2-8 alkenyl, substituted or unsubstituted C2-8 alkynyl, substituted or unsubstituted 3- to 10-membered heterocyclyl, substituted or unsubstituted C6-10 aryl, and substituted or unsubstituted 5- to 10-membered heteroaryl; R3, R4, and R5 are each independently selected from the group consisting of hydrogen, substituted or unsubstituted C1-8 alkyl, substituted or unsubstituted C2-8 alkenyl, substituted or unsubstituted C2-8 alkynyl, substituted or unsubstituted C6-10 aryl, substituted or unsubstituted 5- to 10-membered heteroaryl, and substituted or unsubstituted 3- to 10-membered heterocyclyl; R3 and R4, R4 and R5 or R3 and R5 may, together with the atoms to which they are attached, form a substituted or unsubstituted 5-, 6-, or 7-membered ring; Y4 is selected from the group consisting of -N- and -N+(O)--; L is selected from the group consisting of a bond, -O-, -S-, -S(O)-, S(O)2-, - CR6R7-, -NR8-, -C(O)- and -NR8C(O)-; R6 and R7 are each independently selected from the group consisting of hydrogen, halogen, substituted or unsubstituted C1-8 alkyl, substituted or unsubstituted 3- to 10-membered heterocyclyl, substituted or unsubstituted C2-6 alkenyl, substituted or unsubstituted C2-6 alkynyl, -CN, -OR9, -NR10R11, -S(O)R9, and -S(O)2R9; R6 and R7 may, together with the carbon atom to which they are attached, form substituted or unsubstituted C3-8 cycloalkyl or substituted or unsubstituted 3-to 10-membered heterocyclic ring; R9 is selected from the group consisting of hydrogen, substituted or unsubstituted C1-8 alkyl, substituted or unsubstituted C2-8 alkenyl, substituted or unsubstituted C2-8 alkynyl, substituted or unsubstituted C6-10 aryl, substituted or unsubstituted 5- to 10-membered heteroaryl, and substituted or unsubstituted 3- to 10-membered heterocyclyl; R10 and R11 are each independently selected from the group consisting of substituted or unsubstituted C1-8 alkyl, substituted or unsubstituted 3- to 10-membered heterocyclyl, substituted or unsubstituted C6-10 aryl, substituted or unsubstituted 5- to 10-membered heteroaryl, substituted or unsubstituted C2-8 alkenyl, and substituted or unsubstituted C2-8 alkynyl; R10 and R11 of -NR10R11 may, together with the nitrogen, form a substituted or unsubstituted C3-8 cycloalkyl or substituted or unsubstituted 3- to 10-membered heterocyclyl; R8 is selected from the group consisting of hydrogen, C(O)R12, S(O)2R12, CO2R12, substituted or unsubstituted C1-8 alkyl, substituted or unsubstituted 3- to 10-membered heterocyclyl, substituted or unsubstituted C2-6 alkenyl, and substituted or unsubstituted C2-6 alkynyl; R12 is selected from the group consisting of substituted or unsubstituted C1-8 alkyl, substituted or unsubstituted C2-6 alkenyl, substituted or unsubstituted C2-6 alkynyl, substituted or unsubstituted 3- to 10-membered heterocyclyl, substituted or unsubstituted C6-10 aryl, and substituted or unsubstituted 5- to 10-membered heteroaryl; Z1 is selected from the group consisting of substituted or unsubstituted C6-10 aryl, substituted or unsubstituted 5- to 10-membered heteroaryl, substituted or unsubstituted 3- to 10-membered heterocyclyl, and -NR13R14; R13 and R14 are each independently selected from the group consisting of hydrogen, substituted or unsubstituted C1-8 alkyl, substituted or unsubstituted C2-8 alkenyl, substituted or unsubstituted C2-8 alkynyl, substituted or unsubstituted 3- to 10-membered heterocyclyl, substituted or unsubstituted C6-10 aryl, substituted or unsubstituted 5- to 10-membered heteroaryl, substituted or unsubstituted (C1-4 alkyl)-(C6-10 aryl), and substituted or unsubstituted (C1-4 alkyl)-(5- to 10-membered heteroaryl); R13 and R14 may, together with the nitrogen, form a substituted or unsubstituted 4-, 5-, 6-, or 7-membered heterocyclyl with the proviso that compounds of formula CC are excluded: where X14 is selected from the group consisting of -Cl, -NO2, -OCH3, -CH3, - NHC(O)CH3, and -CH2CH2-(phenyl); R65 is selected from the group consisting of hydrogen, substituted or unsubstituted C1-4 alkyl, and substituted or unsubstituted -SO2(phenyl); and R60 is selected from the group consisting of -NR61CH2CH2OR62, - NR61CH2CH2NR63R64, -NR61CH2CH2SR62, where R61 is selected from the group consisting of hydrogen and substituted or unsubstituted phenyl; R62 is selected from the group consisting of substituted or unsubstituted phenyl, and substituted or unsubstituted C1-4 alkyl; and R63 and R64 are each independently selected from the group consisting of hydrogen, substituted or unsubstituted C1-8 alkyl, substituted or unsubstituted phenyl, substituted or unsubstituted -SO2(phenyl), - C(O)CH3, -C(O)C(O)OH, and -C(O)2C(CH3)3.

  一种具有式(I)或其盐的化合物：其中，Ar选自被取代或未取代的C6-10芳基或被取代或未取代的5-至10元杂芳基；R1选自氢、未取代的C1烷基、被取代或未取代的C3-8烷基、被取代或未取代的C2-6烯基、被取代或未取代的C2-6炔基和被取代或未取代的3-至10元杂环基；Y1选自-CR2a-、-N-和-N+(O)-；Y2选自-CR2b-、-N-和-N+(O)-；Y3选自-CR2c-、-N-和-N+(O)-；R2a、R2b和R2c各自独立地选自氢、卤素、-CN、-C(O)R3、-CO2R3、-C(O)NR3R4、-OR3、-OC(O)R3、-OC(O)NR3R4、-SR3、-S(O)R3、-S(O)2R3、-S(O)2NR3R4、-NO2、-NR3R4、-NR3C(O)R4、-NR3C(O)OR4、-NR3S(O)2R4、-NR3C(O)NR4R5、被取代或未取代的C1-8烷基、被取代或未取代的C2-8烯基、被取代或未取代的C2-8炔基、被取代或未取代的3-至10元杂环基、被取代或未取代的C6-10芳基和被取代或未取代的5-至10元杂芳基；R3、R4和R5各自独立地选自氢、被取代或未取代的C1-8烷基、被取代或未取代的C2-8烯基、被取代或未取代的C2-8炔基、被取代或未取代的C6-10芳基、被取代或未取代的5-至10元杂芳基和被取代或未取代的3-至10元杂环基；R3和R4、R4和R5或R3和R5可与它们所连接的原子一起形成被取代或未取代的5-、6-或7元环；Y4选自-N-和-N+(O)-；L选自键、-O-、-S-、-S(O)-、S(O)2-、-CR6R7-、-NR8-、-C(O)-和-NR8C(O)-；R6和R7各自独立地选自氢、卤素、被取代或未取代的C1-8烷基、被取代或未取代的3-至10元杂环基、被取代或未取代的C2-6烯基、被取代或未取代的C2-6炔基、-CN、-OR9、-NR10R11、-S(O)R9和-S(O)2R9；R6和R7可与它们所连接的碳原子一起形成被取代或未取代的C3-8环烷基或被取代或未取代的3-至10元杂环基；R9选自氢、被取代或未取代的C1-8烷基、被取代或未取代的C2-8烯基、被取代或未取代的C2-8炔基、被取代或未取代的C6-10芳基、被取代或未取代的5-至10元杂芳基和被取代或未取代的3-至10元杂环基；R10和R11各自独立地选自被取代或未取代的C1-8烷基、被取代或未取代的3-至10元杂环基、被取代或未取代的C6-10芳基、被取代或未取代的5-至10元杂芳基、被取代或未取代的C2-8烯基和被取代或未取代的C2-8炔基；-NR10R11中的R10和R11可与氮一起形成被取代或未取代的C3-8环烷基或被取代或未取代的3-至10元杂环基；R8选自氢、C(O)R12、S(O)2R12、CO2R12、被取代或未取代的C1-8烷基、被取代或未取代的3-至10元杂环基、被取代或未取代的C2-6烯基和被取代或未取代的C2-6炔基；R12选自被取代或未取代的C1-8烷基、被取代或未取代的C2-6烯基、被取代或未取代的C2-6炔基、被取代或未取代的3-至10元杂环基、被取代或未取代的C6-10芳基和被取代或未取代的5-至10元杂芳基；Z1选自被取代或未取代的C6-10芳基、被取代或未取代的5-至10元杂芳基、被取代或未取代的3-至10元杂环基和-NR13R14；R13和R14各自独立地选自氢、被取代或未取代的C1-8烷基、被取代或未取代的C2-8烯基、被取代或未取代的C2-8炔基、被取代或未取代的3-至10元杂环基、被取代或未取代的C6-10芳基、被取代或未取代的5-至10元杂芳基、被取代或未取代的(C1-4烷基)-(C6-10芳基)和被取代或未取代的(C1-4烷基)-(5-至10元杂芳基)；R13和R14可与氮一起形成被取代或未取代的4-、5-、6-或7元杂环基；其中排除式CC的化合物：其中，X14选自-Cl、-NO2、-OCH3、-CH3、-NHC(O)CH3和-CH2CH2-(苯基)；R65选自氢、被取代或未取代的C1-4烷基和被取代或未取代的-SO2(苯基)；R60选自-NR61CH2CH2OR62、-NR61CH2CH2NR63R64和-NR61CH2CH2SR62；其中，R61选自氢和被取代或未取代的苯基；R62选自被取代或未取代的苯基和被取代或未取代的C1-4烷基；R63和R64各自独立地选自氢、被取代或未取代的C1-8烷基、被取代或未取代的苯基、被取代或未取代的-SO2(苯基)、-C(O)CH3、-C(O)C(O)OH和-C(O)2C(CH3)3。
• Moyroud, Joel; Guesnet, Jean-Luc; Bennetau, Bernard, Bulletin de la Societe Chimique de France, 1996, vol. 133, # 2, p. 133 - 141
  作者：Moyroud, Joel、Guesnet, Jean-Luc、Bennetau, Bernard、Mortier, Jacques

  DOI：——

  日期：——
• Bennetau, Bernard; Mortier, Jacques; Moyroud, Joel, Journal of the Chemical Society. Perkin transactions I, 1995, # 10, p. 1265 - 1272
  作者：Bennetau, Bernard、Mortier, Jacques、Moyroud, Joel、Guesnet, Jean-Luc

  DOI：——

  日期：——
• PYRROLIDINONES
  申请人：SMITHKLINE BEECHAM CORPORATION

  公开号：EP0584208A1

  公开（公告）日：1994-03-02